-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease is a cognitive brain disease that affects millions of patients worldwide.
Cholinesterase inhibitors are drugs recommended for the treatment of Alzheimer's disease.
For up to five years after the diagnosis, the use of these drugs has consistently benefited from the cognitive aspect, and the mortality rate has also been reduced.
Hong Xu et al, Long Term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality, Neurology (2021).
Hong Xu et al, Long Term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality, Neurology (2021).
There are three drugs (cholinesterase inhibitors) used to treat Alzheimer's disease: galantamine, donepezil, and rivastigmine.
However, the effects of these drugs have been controversial, partly because of relatively few longitudinal studies.
The results showed that, compared with the control group, treatment with cholinesterase inhibitors was associated with a slower decline in cognitive abilities within 5 years, and a 27% reduction in patient mortality.
Compared with the control group, treatment with cholinesterase inhibitors was associated with a slower decline in cognitive abilities within 5 years and a 27% reduction in patient mortality.
"This result provides strong support for recommending the use of cholinesterase inhibitors for the treatment of patients with Alzheimer's disease, and also shows that treatment will last a long time.
Leave a message here
